Syngene International, the contract research division of Biocon Group, developed a fully independent supply chain alternative to China.
Sibaji Biswas, Executive Director and CFO of Syngene International stated, “Syngene has successfully replaced Chinese suppliers with alternatives both within India and internationally”.
Currently, the company provides clients with the flexibility to choose between supply chains that are independent of China and those that still rely on Chinese sources. China remains a cost-effective option due to its high production capacity.
Syngene has witnessed a fifty percent year-on-year increase in requests for proposals (RFPs). The surge follows the recent passage of the Biosecure Act by the US House of Representatives, which was approved recently.
The legislation encourages US pharmaceutical companies to reduce their dependence on Chinese firms citing national security concerns.
While the company has received numerous inquiries and requests for quotes (RFQs) and proposals, the transition is gradual. Companies are approaching the shift with caution, initiating pilot projects to evaluate Syngene’s capabilities, Biswas explained.
Syngene has made significant strides in decreasing its reliance on Chinese suppliers in the small-molecule sector and now sources biologics predominantly from Western countries. The company has also supported Western stockists in establishing stocking points in India to expedite raw material access and strengthen India’s pharmaceutical supply chain.
Syngene works with eleven of the world’s top fifteen biopharma companies. As reported by thehindubusinessline.com, the brands client base is geographically diverse, with 67.9 percent of business coming from the US, 20.8 percent from Europe, and the remainder from East Asia, including Japan, as well as some business from Australia.
